Global Immunohematology Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Immunohematology Market Analysis

The immunohematology market is experiencing robust growth driven by advancements in blood testing technology and the increasing need for safe blood transfusions and patient care. This market encompasses tools and technologies used to match blood types, screen for antibodies, and ensure compatibility between donors and recipients, which are crucial for patient safety in hospitals and trauma centers. Innovations in immunohematology include the use of automation, advanced reagents, and integration of artificial intelligence to improve the accuracy and speed of blood testing. These advancements enhance diagnostic capabilities and contribute to the efficient management of blood resources. The market is also fueled by an aging population and the rising incidence of chronic diseases that require blood transfusions, creating a higher demand for reliable blood screening and typing solutions. Key technological trends include the development of microplate systems, gel card technologies, and automated analyzers, which streamline laboratory operations and reduce the risk of human error. As hospitals and diagnostic laboratories continue to adopt these technologies, the immunohematology market is set to expand, supported by increasing investments and strategic collaborations within the healthcare sector.

Immunohematology Market Size

The global immunohematology market size was valued at USD 2.05 billion in 2024 and is projected to reach USD 2.85 billion by 2032, with a CAGR of 4.19% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Immunohematology Market Trends

“Increasing Use of Automation and Digital Technologies”

A notable trend in the immunohematology market is the increasing use of automation and digital technologies to enhance the efficiency and accuracy of blood testing procedures. Automated systems, such as the gel card technology and advanced microplate analyzers, are gaining traction as they streamline blood typing and antibody screening processes while minimizing human error. For incidence, Siemens Healthineers' automated immunohematology analyzers improve workflow in blood banks and diagnostic laboratories by rapidly processing samples with high precision. These innovations boost the throughput of testing and reduce turnaround time, supporting the growing demand for safe and efficient blood transfusions. The integration of digital solutions, including data management platforms, also allows healthcare providers to monitor and track blood compatibility in real-time, ensuring patient safety and optimizing resource management. This trend towards automation is set to drive the immunohematology market, meeting the needs of an increasing patient population and advancing clinical practices.

Report Scope and Immunohematology Market Segmentation

Immunohematology Market Definition

Immunohematology is a branch of medical science that focuses on the study of blood and its components, specifically the interactions between blood antigens and antibodies. It involves testing and analyzing blood to determine blood type, screen for antibodies, and ensure compatibility for blood transfusions. This field is crucial for patient safety, as it helps prevent adverse reactions during blood transfusions by ensuring that the donor's blood matches the recipient's blood type and does not contain antibodies that could cause complications.

Immunohematology Market Dynamics

Drivers

• Growing Number of Blood Banks and Trauma Centers

The growing number of blood banks and trauma centers is a significant driver for the immunohematology market, as these facilities play a crucial role in providing timely and safe blood transfusions. According to the World Health Organization (WHO), approximately 118.5 million blood donations are collected globally each year, with a large proportion of these sourced from blood banks to support medical procedures and emergency care. The increasing number of trauma centers, especially in developing and developed countries, is also driving the demand for reliable blood testing and compatibility solutions to manage emergency cases efficiently. This rise in healthcare infrastructure highlights the need for advanced immunohematology technologies that ensure blood safety, optimize blood resource management, and prevent transfusion-related complications. Consequently, the growth of blood banks and trauma centers is boosting the demand for automated blood typing and antibody screening systems, contributing to the expansion of the immunohematology market.

• Rising Incidence Rate of Various Hematological Disorders

The rising incidence rate of various hematological disorders is a key driver for the immunohematology market, as it necessitates increased blood testing and transfusion services. For instance, according to the American Society of Hematology, over 1.5 million new cases of hematologic cancers such as leukemia, lymphoma, and multiple myeloma are diagnosed each year globally, emphasizing the critical need for accurate blood compatibility testing and patient monitoring. In addition, conditions such as sickle cell disease and thalassemia, which are prevalent in certain regions, require regular blood transfusions, further driving the demand for efficient immunohematology solutions. This trend is prompting hospitals and diagnostic laboratories to adopt advanced technologies such as automated blood analyzers and high-throughput screening tools, which ensure quick and precise blood typing and antibody screening. As the prevalence of hematological disorders continues to rise, the immunohematology market is expected to grow, fueled by the need for reliable and effective blood testing to manage and treat these conditions.

Opportunities

• Increasing Incidence of Blood Cancer

The increasing incidence of blood cancer presents a significant market opportunity for the immunohematology sector, as effective management and treatment of these cancers rely heavily on accurate blood testing and compatibility assessments. For instance, the American Cancer Society reports that over 176,000 cases of blood cancers, including leukemia, lymphoma, and multiple myeloma, are expected to be diagnosed in the U.S. alone in 2024. This growing patient population underscores the need for advanced immunohematology solutions that can support blood transfusions, bone marrow transplants, and other treatment procedures that are vital for managing blood cancer. The adoption of technologies such as automated blood analyzers and integrated data management systems enhances the accuracy and efficiency of blood testing, leading to better patient outcomes and more streamlined operations in hospitals and specialized treatment centers. As the incidence of blood cancer continues to rise globally, the demand for reliable immunohematology products and services is set to grow, creating substantial opportunities for market players to expand and innovate.

• High Growth of Innovative Technologies and Product Launches

The high growth of innovative technologies for blood screening and the continuous introduction of new products present a significant market opportunity for the immunohematology industry. Advances such as automated blood analyzers, microplate systems, and gel card technologies have enhanced the accuracy, speed, and efficiency of blood typing and antibody screening processes. For instance, Siemens Healthineers’ new automated immunohematology analyzers have streamlined blood testing procedures in blood banks and hospitals, improving patient safety and operational productivity. In addition, the market has seen the launch of novel products such as F. Hoffmann-La Roche Ltd.'s blood screening assays, which offer faster and more reliable detection of blood antigens and antibodies. The development and adoption of these cutting-edge technologies cater to the increasing demand for efficient and accurate blood screening and support the growing need for safe blood transfusions and patient care. As such, the proliferation of innovative technologies and new product launches positions the immunohematology market for significant growth and expansion.

Restraints/Challenges

• Strict Regulatory Policies

Strict regulatory policies pose a significant challenge for the immunohematology market, as companies must comply with comprehensive standards to ensure the safety and effectiveness of blood testing and screening products. For instance, in the U.S., the Food and Drug Administration (FDA) enforces rigorous requirements for blood testing equipment and reagents to ensure patient safety, which can lead to long approval timelines and higher development costs. Similarly, the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR) imposes strict guidelines that manufacturers must meet before their products can be marketed. These regulations necessitate extensive clinical testing and documentation, which can be time-consuming and financially demanding for companies. The complexity and cost associated with meeting these regulatory standards can slow down the introduction of innovative solutions, potentially limiting market growth. As a result, while regulatory policies aim to protect patient health, they also present hurdles that can impede the timely deployment and scalability of new technologies within the immunohematology sector.

• Lack of Skilled Professionals

The lack of skilled professionals in the immunohematology field presents a market opportunity for companies to develop and introduce advanced training programs and user-friendly technologies that can bridge this skills gap. With the increasing demand for sophisticated blood screening and testing solutions, the shortage of well-trained laboratory technicians and healthcare professionals can impact the efficiency and accuracy of blood transfusion services. For instance, as blood banks and hospitals adopt automated and high-throughput analyzers, the need for professionals who are proficient in operating these advanced systems becomes crucial. Companies can seize this market opportunity by offering comprehensive training programs, online courses, and certifications designed to equip healthcare workers with the expertise needed to use new immunohematology technologies effectively. In addition, the development of intuitive, easy-to-use equipment can help reduce the learning curve for new users and improve the overall workflow in clinical and diagnostic settings. By addressing this shortage, the market can improve service quality and support the growing demand for reliable blood testing and transfusion services.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Immunohematology Market Scope

The market is segmented on the basis of product type, technology, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Immunohematology Analyzer
• Immunohematology Reagent

Technology

• Microplates
• Biochips
• Gel Cards
• Erythrocyte-Magnetized Technology (EMT)
• Polymerase Chain Reaction (PCR)

Application

• Antibody Screening
• Blood Typing

End User

• Blood Banks
• Hospitals
• Diagnostic and Reference Laboratories
• Academic and Research Institutes

Immunohematology Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, technology, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is at the forefront of the immunohematology market due to the growing number of trauma centers and blood bank facilities across the area. This increase in healthcare infrastructure is driven by the region's focus on improving emergency care and blood management capabilities. In addition, advancements in technology and a strong emphasis on patient safety and efficient blood transfusion practices contribute to the market's growth. These factors make North America a dominant player in the immunohematology sector, supporting both medical advancements and public health needs.

Asia-Pacific is anticipated to witness significant growth in the immunohematology market from 2025 to 2032, driven by the strong presence of leading industry players and global healthcare companies. This region benefits from continuous investments in healthcare infrastructure and advanced technologies, which support the development and deployment of immunohematology solutions. In addition, the increasing demand for high-quality diagnostic and blood management systems, along with rising awareness of patient care, contributes to market expansion. The strategic initiatives by major companies and government support for healthcare improvements are expected to further boost the region's growth during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Immunohematology Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Immunohematology Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific Inc. (U.S.)
• Hologic, Inc. (U.S.)
• Merck KGaA (Germany)
• Beckman Coulter, Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• Grifols, S.A. (Spain)
• Cardinal Health (U.S.)
• CSL (Australia)
• QuidelOrtho Corporation (U.S.)
• Werfen, S.A. (Spain)
• BD (U.S.)
• HORIBA, Ltd. (Japan)
• Abbott (U.S.)
• MTC INVITRO DIAGNOSTICS AG (Switzerland)
• ANTISEL (France)
• Danaher (U.S.)
• Sysmex Corporation (Japan)
• GSG ROBOTIX (Italy)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bio-Rad Laboratories, Inc. (U.S.)

Latest Developments in Immunohematology Market

• In January 2024, the U.S. market saw the launch of the HemoFlow 500 Series, marking a significant advancement in blood scale and mixer technology. These next-generation devices are designed to enhance the efficiency and precision of blood sample processing in clinical and laboratory settings. The launch is expected to improve workflow and accuracy, meeting the growing demands for high-quality blood testing and analysis.
• In November 2023, Versiti completed the acquisition of Pearl Pathways, an Indianapolis-based firm specializing in regulatory consulting and clinical trials. This strategic acquisition is aimed at strengthening Versiti's capabilities in advancing regulatory processes and enhancing its research and development efforts. The move is expected to expand Versiti's influence in the field of blood and biopharmaceutical research
• In July 2023, QuidelOrtho announced a collaboration with BYG4lab to enhance its informatics offerings. This partnership is set to integrate innovative data management solutions and digital health technology to streamline laboratory operations. The collaboration aims to improve data accessibility and optimize the quality of diagnostic and transfusion services
• In May 2022, Nihon Kohden Corporation, a leading medical technology company, established a new hematology analyzer reagent factory in India. This strategic expansion is intended to meet the growing demand for advanced diagnostic tools and reagents in the region. The move is expected to strengthen Nihon Kohden's presence and service capabilities within the South Asian market
• In April 2022, Sysmex Europe launched the XQ-320 XQ-Series Automated Hematology Analyzer, a new three-part differential system. This innovative analyzer is equipped with advanced features for quality control and data security, supporting more accurate and efficient patient diagnostics. The XQ-320 is designed to enhance laboratory productivity and improve the safety and reliability of patient data management
• In January 2021, Thermo Fisher Scientific Inc. acquired Mesa Biotech, Inc. to strengthen its molecular diagnostic segment. This strategic move is expected to help the company capture a larger share of the market for PCR-based rapid point-of-care testing solutions

SKU-59949